AAA June 2018 – Page 5

Xeris reformulates path to IPO

Xeris Pharmaceuticals, a US-based drug formulation developer backed by drug producer Institut Mérieux, went public on Friday after issuing 5.7 million shares priced at $15 each, raising $85.5m. The company’s shares opened at $19.50 on the Nasdaq Global Market on Friday. After briefly rising to $19.84 they closed at $18.80. Xeris has developed two formulation… Continue reading Xeris reformulates path to IPO